# Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure

> **NCT07694297** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Genfit** · enrollment: 16 (estimated)

## Conditions studied

- Acute Decompensation of Liver Cirrhosis
- Established Acute-on-Chronic Liver Failure

## Interventions

- **DRUG:** NTZ 500mg BID on top of SOC

## Key facts

- **NCT ID:** NCT07694297
- **Lead sponsor:** Genfit
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-08
- **Final completion:** 2027-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694297, "Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*